Healthcare practice
Healthcare software, engineered to clinical standard, since 2021.
FHIR-R4-conformant integrations. HIPAA-ready infrastructure. SOC2 Type II. A named engineering principal owns every engagement and signs the SOW. Our flagship is Kimera P-IV — a point-of-care plasmonic RT-qPCR platform built on a decade of peer-reviewed McGill / Lady Davis Institute research and commercialized by NEXLESS.
NEXLESS Healthcare
Kimera P-IV Plasmonic RT-qPCR diagnostics, KimeraWorks bespoke solutions, and our clinical PCR practice — on their own dedicated site.
Peer-reviewed research
The plasmonic PCR science behind Kimera P-IV — in the literature.
The Kimera P-IV platform is built on a decade of peer-reviewed work on plasmonic, ultrafast, label-free PCR — a McGill / Lady Davis Institute collaboration commercialized by NEXLESS. The published record:
- Performance and functional assessment of the Kimera P-IV point-of-care plasmonic qPCR prototype for ultra-rapid pathogen detection of Chlamydia trachomatis
Hayes, Lee, Carnevale, Shamir, Bohbot, Kirk, Paliouras, Trifiro · Epidemiology & Infection · 2025
Validates the four-channel Kimera P-IV prototype — gold nanorods as nano-heaters, VCSEL lasers in place of Peltier blocks — running 30 cycles in under 13 minutes at sub-10-copy sensitivity, including direct-from-urine analysis.
- Assessing Different PCR Master Mixes for Ultrarapid DNA Amplification: Important Analytical Parameters
Brukner, Paliouras, Trifiro, Bohbot, Shamir, Kirk · Diagnostics (Basel) · 2024
Benchmarks commercial PCR master mixes under extreme plasmonic cycling (1–5 s anneal/elongation), showing enzyme biochemistry governs the reliability of ~10-minute ultrafast amplification.
- Plasmonic and label-free real-time quantitative PCR for point-of-care diagnostics
Mohammadyousef, Paliouras, Trifiro, Kirk · Analyst (RSC) · 2021
A plasmonic thermocycler with real-time, fluorophore-free (UV-absorption) amplicon detection — quantitative PCR without labels.
- Real-time plasmonic qPCR: how fast is ultra-fast? 30 cycles in 54 seconds
Roche, Najih, Lee, Beitel, Carnevale, Paliouras, Kirk, Trifiro · Analyst (RSC) · 2017
The foundational ultrafast-thermocycling result for the group: optically-heated metallic-nanoparticle PCR completing 30 cycles in 54 seconds.
- Ultrafast plasmonic and real-time label-free PCR for point-of-care diagnostics (PhD thesis)
Mohammadyousef · advisor A. G. Kirk · McGill University · 2021
First demonstration of a compact plasmonic thermocycler with suspended gold-nanorod photothermal heating and real-time label-free quantitative detection.
Lab: Photonic Biosensing Lab, McGill University (Prof. Andrew Kirk).
Compliance posture
Half the security questionnaire is already answered here.
Procurement teams scan this section first. We surface it first. Each posture below is a single declarative statement; the linked public documentation carries the audit-grade detail. Where the documentation is under NDA, the discovery call is the path.
- SOC2 Type II
- Audit report available under NDA in the discovery call.
- HIPAA-ready
- Business Associate Agreements signed with all hosted-PHI clients. Encryption at rest (AES-256) and in transit (TLS 1.3). Key rotation policy: 90 days.
- FHIR R4 conformant
- Integrations against Epic, Cerner, and Allscripts gateways. Public conformance statement at /compliance/fhir-conformance once published.
- Clinical workflow grounded
- Every healthcare engagement includes a clinical advisor on the build team. We do not ship UI to nurses or physicians without their input on the workflow.
Named product · Kimera P-IV
Kimera P-IV is a point-of-care plasmonic RT-qPCR platform — molecular diagnostics at the speed of a clinic visit.
Kimera P-IV replaces the bench thermocycler with optics. Gold nanorods act as nano-heaters and VCSEL lasers drive the thermal cycling in place of Peltier blocks, so a full 30-cycle real-time qPCR run completes in under thirteen minutes instead of the better part of an hour. The four-channel platform reaches sub-10-copy sensitivity and has been demonstrated running directly from urine — no separate extraction step in front of the assay.
The platform is the commercial end of roughly a decade of peer-reviewed work on plasmonic, ultrafast, label-free PCR — a McGill University / Lady Davis Institute collaboration that NEXLESS commercializes. The science is not a claim on a slide: it is the published record in the section above, from the foundational “30 cycles in 54 seconds” result through the Kimera P-IV functional assessment for Chlamydia trachomatis.
We are deliberate about what Kimera P-IV is. It is a diagnostic instrument and assay platform, not a black-box algorithm — every performance figure on this page traces to a specific peer-reviewed paper and a specific validated build. The companion software, compliance posture, and bespoke KimeraWorks engagements live on the dedicated NEXLESS Healthcare site.
Engineering approach
We engineer the diagnostic and the software around it.
The stack is opinionated and earns its opinions case-by-case. Next.js 14 on the application tier; Python 3.12 with FastAPI for FHIR-facing services and SQLAlchemy 2.0 over PostgreSQL with row-level security policies per tenant. The instrument-control and assay-data path is held to the same standard as the clinical software it feeds.
When a deployment needs to talk to a hospital’s record system, FHIR integrations live in their own adapter package — one module per major EHR family (Epic, Cerner, Allscripts, Athenahealth), each conforming to the same internal interface so the differences between EHRs stay in the adapter layer, not the application code.
On-call is a stated commitment, not a contractual gesture. Any engagement we operate carries a 24/7 rotation with a small roster (so context is preserved across the rotation) and a published Sev-1 initial-response SLA, with the runbook co-authored with the client’s SRE team.
We sign Business Associate Agreements with every client whose Protected Health Information passes through systems we operate. PHI never sits in a development environment; the synthetic patient generator that drives our integration tests is reviewed by clinicians on our team for medical plausibility before cases enter the corpus.
Where we explicitly do not ship: front-line clinical UI without a clinician on the build team, and any system that depends on a vendor SDK we cannot replace within ninety days.
Where it stands
Kimera P-IV is validated and production-ready, with its results in the peer-reviewed record.
The four-channel Kimera P-IV platform has been functionally assessed for ultra-rapid detection of Chlamydia trachomatis, with the results published in Epidemiology & Infection (2025). It completes 30 real-time qPCR cycles in under thirteen minutes, resolves down to fewer than ten target copies, and has run directly from urine without a separate extraction step.
Those figures are not internal benchmarks — they are the published, peer-reviewed record linked in the research section above, the product of a McGill / Lady Davis Institute collaboration that NEXLESS commercializes. The platform is production-ready: we are engaging clinical and laboratory partners deploying point-of-care molecular diagnostics that run at the speed of a visit.
If you operate a lab or clinic and want to evaluate the platform, the discovery call is the path — and the dedicated NEXLESS Healthcare site carries the deeper technical and compliance detail.
- Throughput
- 30 cycles in <13 minutes
- Sensitivity
- Sub-10-copy detection
- Sample
- Direct-from-urine demonstrated
- Evidence
- Epidemiology & Infection, 2025